Celebrating our graduating Yale Hematology Oncology Fellows fellows! 🎓🎉🪩 It's been a long journey to this final training milestone... HUGE CONGRATULATIONS to this phenomenal group of clinicians, researchers, citizens, and friends. We are so excited for everyone's next chapters. 🥹🫂👏🥳

We are hiring! Our lab is seeking a postgraduate associate interested in cancer biology and metabolism to work on our new R01-funded project exploring the links between fatty acids and #PancreaticCancer. Please RT! Yale Cancer Center Yale Cancer Biology Institute Yale Department of Genetics apply.interfolio.com/120087

Kudos to Cathy C Garcia and Jeremy B. Jacox, MD PhD for presenting amazing posters at @aacr #AACRpan23! Lots of engagement by the #PancreaticCancer research community based on the crowds around them and the hoarseness of their voices! Yale Cancer Center Yale Department of Genetics Yale Cancer Biology Institute Lustgarten Foundation

Register to join us tomorrow, November 16 at 7pm, on #WorldPancreaticCancerDay for a webinar highlighting the latest treatment advances for #PancreaticCancer with Muzumdar Lab Sajid Khan Jill Lacy Yale Cancer Center Center for Gastrointestinal Cancers Pamela Kunz, MD, FASCO Yale School of Medicine RSVP ➡️ bit.ly/49iVSTO

.David Braun beautifully illustrates how to modulate the immune system to treat renal cell carcinoma #RCC by looking at T cell immunity as a car driving towards a tumor. #ASCO24 #kidneycancer Smilow Cancer Hospital Yale School of Medicine Yale New Haven Hosp OncoAlert

Huge shoutout to our Yale Fellows Tendai, Rebecca, and Yiduo for this incredible accomplishment of ASCO YIA this #ASCO24! Excited to see what you discover. And grateful to Conquer Cancer, the ASCO Foundation for their ongoing support of early career researchers (including myself at #ASCO23)!

#ASCO24 ASCO #PCsm #PASS01 Dr. Jennifer Knox, IIT 🇨🇦 📌 multiomic profiling, Rph2 mFFX vs GnP 📌 n=160, ~30% basal/70% classical 👉early results - PFS/OS - mFFX was not better than GnP in this cohort excl gBRCA/PALB2 👉outcomes in pancreatic cancer remain poor 👏rich

Stunning interim clinical trial data from Revolution Medicines... PFS = 8.1 mo in 2nd line KRAS G12-mutant metastatic #PDAC. OS not yet reached, but already more than a year! Benchmark PFS for this group is 2-3.5 months, behnchmark OS is 6.1-6.9. 1/

Congrats Dr. Cathy C Garcia on a riveting Yale PhD defense yesterday! Cathy is brilliant, persevering, and exceptionally kind, and it has been an honor to work literally right next to her these last 3 years Muzumdar Lab . Huge kudos as you spread your wings to Stanford University, Cathy!

🛡️ Cancer cells use "3 Cs" to evade the immune system: 1️⃣ Camouflage: Hiding from immune detection. 2️⃣ Coercion: Disrupting immune function. 3️⃣ Cytoprotection: Shielding from immune attacks. Blocking these mechanisms enhances immunotherapy and restores anticancer immune

And this fits nicely and precisely into our framework for the development of the pancreatic cancer tumor microenvironment!

Excited for the annual Yale Cancer Biology Institute retreat kicked off by our very own students #CassieBishop and Gigi Ge on #KRAS, THE driver oncogene in #PancreaticCancer. Looking forward to great science, conversations, collaborations, and fun! Yale Cancer Center Yale West Campus

Excited to share our preprint confirming an essential role of the oft forgotten beta cell in #PancreaticCancer development. Yale Cancer Center Yale Cancer Biology Institute Yale Department of Genetics biorxiv.org/content/10.110…

News: Combination therapy shrank a variety of metastatic solid tumors bit.ly/3E1tACl

Federal pancreatic cancer research funding was eliminated in the FY25 budget — but we’re not backing down. Right now, there's a letter circulating in the House calling for $25 million to restore and strengthen the dedicated pancreatic cancer research program YOU helped create.

Congratulations to each of these amazing Yale oncology colleagues—Mariya, Amin, Ben, Devora and Nicole—on their trailblazing work recognized by Conquer Cancer!!!